Catalytica Manufacturing Problems Cited In Recalls, Approval Delays
Executive Summary
Idec is considering using a third-party certification as a short cut to resolving FDA's remaining questions about Catalytica's fill/finish manufacturing process for the lymphoma therapy Zevalin
You may also be interested in...
DSM Submits “Final” GMP Report To FDA; New Quality Systems In Place
DSM Pharmaceuticals is highlighting new environmental monitoring systems in its response to FDA about recent good manufacturing practices inspections
DSM Submits “Final” GMP Report To FDA; New Quality Systems In Place
DSM Pharmaceuticals is highlighting new environmental monitoring systems in its response to FDA about recent good manufacturing practices inspections
Manufacturing Issues Delay Half Of Pending BLAs, CBER’s Yetter Says
Half of the active pending BLAs at the Office of Therapeutics Research & Review as of Jan. 1 have manufacturing concerns, Center for Biologics Evaluation & Research Associate Director-Review Management Robert Yetter, PhD, said